Conditions ripe for Swiss company takeovers and mergers
Novartis shed its stake in cross-town rival Roche last year worth CHF21 billion.
Keystone / Georgios Kefalas
Rock bottom interest rates and excess cash sloshing around Swiss companies saw a three-fold increase in the value of mergers and acquisitions (M&A), rising to CHF170 billion ($186 billion) last year.
This content was published on
1 minute
swissinfo.ch/mga
العربية
ar
الظروف مهيئة لعمليات الاستحواذ والاندماج بين الشركات السويسرية
The corporate shopping spree was led by the pharmaceutical and life science sectors, which have seen increased business during the Covid-19 pandemic.
The biggest deal of 2021 saw Novartis relinquish its stake in pharmaceutical rival Roche, which was worth CHF21 billion.
The pharmaceutical and life science sectors saw M&A deal activity surge from CHF6 billion in 2020 to CHF56 billion last year, comprising four of the ten largest corporate deals.
The technology, media and telecommunications industries also saw increased activity.
The sectors “have been very consistent in pursuing innovation over the past two pandemic years, and we expect that to continue this year with well-targeted investments,” said Roger van den Heuvel of consultancy company KPMG, which compiled the report.
Most transactions (46%) involved Swiss firms acquiring stakes in foreign companies, double the volume of overseas corporations taking over Swiss counterparts.
Popular Stories
More
Climate adaptation
Why Switzerland is among the ten fastest-warming countries in the world
Has your continent reached its peak or is there still potential for economic growth?
Some regions of the world are on an upward trajectory with the promise of a steadily improving future. Where do you live? And in which direction is your region or continent developing?
Living longer: What do you think about the longevity trend?
The longevity market is booming thanks in part to advances in the science of ageing. What do you think of the idea of significantly extending human lifespan?
US tariffs: Pharma firms not planning job cuts in Switzerland
This content was published on
The additional investments in the US will not lead to a reduction in jobs in Switzerland. This is according to pharmaceutical giant Roche, which expects the number of employees to remain stable in the current year. The position of Novartis is similar.
Switzerland is closely monitoring three livestock diseases
This content was published on
The spread of Lumpy skin disease, Bluetongue and African swine fever are keeping Swiss veterinary authorities on the alert.
Swiss writer wins European Prize for Political Culture
This content was published on
On Saturday, the Hans Ringier Foundation awarded the 91-year-old Zurich writer Adolf Muschg the European Prize for Political Culture.
Swiss government working with firms to overcome high US tariffs
This content was published on
The Swiss delegation that travelled to Washington has returned from talks on tariffs in the United States. The negotiations are now being conducted under the aegis of the government and the federal administration, according to Seco.
WTO improves its world trade forecast thanks to Trump’s tariffs
This content was published on
The World Trade Organisation (WTO) expects world trade to grow by 0.9% this year, better than expected in April. US imports surged in the first quarter as a result of Donald Trump's tariff announcements.
Swiss gold exports might not face US tariffs after all
This content was published on
Gold exports to the United States may not be taxed after all. The White House plans to "issue an executive order in the near future to clarify misinformation regarding the taxation of gold bullion," among other things.
Swiss firms in record number of mergers and acquisitions
This content was published on
The number of merger and acquisition deals involving Swiss companies hit a record high in 2018, according to a report by consultancy firm KPMG.
Swiss government rejects takeover restrictions on Chinese firms
This content was published on
The Swiss government has dismissed talk of introducing investment controls on Chinese companies despite requests from parliament to examine the risks.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.